Alport Syndrome clinical trials at University of California Health

• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

  open to eligible people ages 12 years and up

  This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

  at UCLA UCSF

• Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

  open to eligible people ages 18-55

  Primary Objectives: - To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function - To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: - To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites - To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375) - To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.

  at UCLA

Last updated: December 14, 2021